Aclarubicin: Difference between revisions
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 4: | Line 4: | ||
| verifiedrevid = 477240878 | | verifiedrevid = 477240878 | ||
| IUPAC_name = (1''S'',2''S'',4''R'')-Methyl 4-(((2''S'',5''R'',6''R'')-4-(dimethylamino)-5-(((1''S'',3''R'',4''S'')-3-hydroxy-5-methyl-4-(((2''S'',6''R'')-6-methyl-5-oxotetrahydro-2''H''-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2''H''-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate | | IUPAC_name = (1''S'',2''S'',4''R'')-Methyl 4-(((2''S'',5''R'',6''R'')-4-(dimethylamino)-5-(((1''S'',3''R'',4''S'')-3-hydroxy-5-methyl-4-(((2''S'',6''R'')-6-methyl-5-oxotetrahydro-2''H''-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2''H''-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate | ||
| image = Aclarubicin. | | image = Aclarubicin.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
Line 57: | Line 57: | ||
| StdInChIKey = USZYSDMBJDPRIF-UHFFFAOYSA-N | | StdInChIKey = USZYSDMBJDPRIF-UHFFFAOYSA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Aclarubicin''' ([[International Nonproprietary Name|INN]]) or '''aclacinomycin A'''<ref name="pubchem">{{PubChem|451415}}</ref> is an [[anthracycline]] drug<ref name="pmid1655244">{{cite journal |author=Jensen PB, Jensen PS, Demant EJ, ''et al.'' |title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II |journal=Cancer Res. |volume=51 |issue=19 |pages=5093–9 |date=October 1991 |pmid=1655244 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1655244}}</ref> that is used in the treatment of [[cancer]]. Soil bacteria ''[[Streptomyces galilaeus]]'' can produce aclarubicin. | '''Aclarubicin''' ([[International Nonproprietary Name|INN]]) or '''aclacinomycin A'''<ref name="pubchem">{{PubChem|451415}}</ref> is an [[anthracycline]] drug<ref name="pmid1655244">{{cite journal |author=Jensen PB, Jensen PS, Demant EJ, ''et al.'' |title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II |journal=Cancer Res. |volume=51 |issue=19 |pages=5093–9 |date=October 1991 |pmid=1655244 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1655244}}</ref> that is used in the treatment of [[cancer]]. Soil bacteria ''[[Streptomyces galilaeus]]'' can produce aclarubicin. | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} |
Latest revision as of 19:23, 6 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C42H53NO15 |
Molar mass | 811.86 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Aclarubicin |
Articles |
---|
Most recent articles on Aclarubicin Most cited articles on Aclarubicin |
Media |
Powerpoint slides on Aclarubicin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Aclarubicin at Clinical Trials.gov Clinical Trials on Aclarubicin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Aclarubicin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Aclarubicin Discussion groups on Aclarubicin Patient Handouts on Aclarubicin Directions to Hospitals Treating Aclarubicin Risk calculators and risk factors for Aclarubicin
|
Healthcare Provider Resources |
Causes & Risk Factors for Aclarubicin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.
References
- ↑ Template:PubChem
- ↑ Jensen PB, Jensen PS, Demant EJ; et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244.
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Anthracyclines
- Topoisomerase inhibitors